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58 The Journal of Thoracic and Cardiobjective: To compare explantation for structural valve deterioration in nonelderly
atients after aortic valve replacement with stented bovine pericardial and cryopre-
erved allograft valves.
ethods: From 1981 to 1985, 478 patients received pericardial prostheses during
remarket approval; from 1987 to 2000, 744 patients received cryopreserved allo-
rafts. Mean age of patients receiving allografts was 49 12 years, and that of those
eceiving pericardial prostheses was 65  11 years; pericardial valves were used in
38 patients younger than age 60. Mean follow-up was 15  5.1 years for
ericardial valves (4674 patient-years of follow-up) and 5.6  3.1 years for
llografts (3892 patient years of follow-up). Multivariable hazard function method-
logy, age-group stratification, and propensity matching were used to compare
ge-specific explantation for structural valve deterioration.
esults: Ninety-five pericardial valves and 46 allografts were explanted, and struc-
ural valve deterioration was the mechanism of failure in 74% and 59%, respec-
ively. The risk of structural valve deterioration increased with younger age at
mplantation for both allografts (P  .07) and pericardial valves (P  .0001), with
similar magnitude of effect in patients age 50 years or younger (P  .5), 50 to 60
ears (P  .7), and greater than 60 years (P  .9) and in propensity-matched pairs
P  .2). Thus, pericardial valves were as durable as allografts at all adult ages.
onclusions: Structural valve deterioration is the most frequent cause of valve-
elated reoperation after both pericardial and allograft aortic valve replacement and
s similarly age dependent, suggesting that pericardial valves may be appropriate for
onelderly as well as older persons.
he durability of both allografts and stented xenografts used for aortic valve
replacement has long been linked to patient age: the younger the patient, the
shorter the durability.1-6 By conventional guidelines, both porcine xenografts
nd bovine pericardial stented bioprostheses have been used nearly exclusively in
atients older than 65 years, and allografts have been recommended for those with
nfective endocarditis and for younger patients, for whom lifelong anticoagulation
s undesirable.7 Increasingly, patients are requesting valve alternatives that do not
equire anticoagulation.
Allografts have been preferentially chosen for younger patients at this institution
ecause of the perception that they were more durable than stented bioprostheses,
espite the increased technical complexity of inserting and removing them. How-
ver, extensive experience with, and long-term follow-up of, bovine pericardial
ortic bioprostheses, including inserting them in patients younger than 65 years in
vascular Surgery ● March 2006
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CDremarket testing, has led us to challenge this preference.8
hus, the objectives of the study were to (1) determine the
ndications for explanting allografts and stented bovine peri-
ardial prostheses used for aortic valve replacement, (2)
ompare time-related rates of explantation for structural
alve deterioration (SVD) as a function of age for these 2
evices, (3) compare reoperative risk, and (4) infer from this
nformation the rationality of using a pericardial biopros-
hesis in nonelderly adults.
atients and Methods
atients
Pericardial prostheses. Clinical investigation of the Carpentier-
dwards stented bovine pericardial bioprosthesis (PERIMOUNT;
dwards Lifesciences LLC, Irvine, Calif) began in 1981. Between
eptember 1981 and January 1984, 267 patients with isolated
ortic valve disease (with or without ischemic heart disease) had
his prosthesis implanted at 1 of 4 centers as part of the premar-
eting clinical investigation for the US Food and Drug Adminis-
ration. Results of its durability to 17 years after implantation have
een reported,8 and the follow-up used for this study extended to
0 years. To these 267 patients were added 211 who received the
rosthesis for non–isolated aortic valve disease during this time
rame and through July 1985 at The Cleveland Clinic Foundation.
hese 478 patients form the pericardial prosthesis arm of the
omparison.
Although mean age at implantation was 65  11 years (range,
1-86 years), 138 (29%) were younger than 60 years (Table 1).
Cryopreserved allografts. Between February 2, 1987, and Jan-
ary 1, 2000, 744 patients received a cryopreserved aortic allograft
CryoLife, Inc, Kennesaw, Ga) at The Cleveland Clinic Foundation.
hese individuals were younger (mean age, 49  12 years; range,
8-84) than those receiving pericardial prostheses (P  .0001), with
09 (82%) younger than age 60. This difference and other differ-
nces in patient characteristics and operative details are presented
n Table 1. These same characteristics are presented for patients
ounger than 60 years in Table E1.
Choice of prosthesis. Except for preferential use of allografts
or endocarditis, we were unable to determine why one or the other
alve was chosen for an individual patient. During the years of this
tudy, it was thought that allografts, inserted as a root, were
niquely free of an age effect on SVD (except in children), with
urability likely to extend beyond 25 years.9 Similarly, modifica-
ions in design and preparation of the pericardial valve were
xpected to improve durability and make it a reasonable alternative
o mechanical prostheses in nonelderly patients. These assump-
ions led to age heterogeneity, which afforded us the opportunity to
ompare age-specific explantation for SVD between these 2 types
Abbreviations and Acronyms
CL  confidence limit
SVD structural valve deteriorationf prosthesis. 1
The Journal of Thoracicurgical Technique
ortic valve replacement with pericardial prostheses was per-
ormed using standard techniques.10 Allografts were inserted as a
oot in 718 patients (96.5%) and by the subcoronary technique in
6 (3.5%).11
ollow-up
Pericardial prostheses. Patient status in the multi-institutional
remarket cohort was assessed annually, and the additional Cleve-
and Clinic cohort was assessed every 2 years,8 typically during an
ffice or hospital visit or by means of detailed institutional review
oard–approved patient questionnaires completed by telephone or
ail. Mean follow-up among survivors was 15  5.1 years (max-
mum, 20 years), and 4664 patient-years of data were available for
nalysis. We considered time-related estimates to be reliable to
9 years.
Cryopreserved allografts. Patients were routinely followed at
-year intervals by questionnaire, supplemented by cross-sectional
ollow-up in 2002. Mean follow-up among survivors was 5.6 
.1 years; 10% of patients were followed more than 10 years, 5%
ere followed more than 12 years, and maximum follow-up was
ABLE 1. Patient characteristics and operative details
Pericardial*
(n  478)
Allograft †
(n  751)
ariable No. % No. % P value
ge (y) .0001
30 5 1.0 47 6.3
30-40 19 4.0 154 21
40-50 27 5.6 205 27
50-60 87 18 203 27
60-70 185 39 98 13
70 155 32 37 4.9
ender .0001
Men 297 62 555 74
Women 181 38 189 25
YHA class .0001
I 52 11 138 18
II 239 50 397 53
III 138 29 164 22
IV 45 9.5 44 5.9
Unavailable 4 1
revious cardiac operation 44 9.2 232 31 .0001
ndocarditis 26 5.4 189 25 .0001
oncomitant procedure
Repair or replacement of
another valve
Mitral repair 20 4.2 87 12 .0001
Mitral replacement 35 7.3 9 1.2 .0001
Tricuspid repair 2 0.4 14 1.9 .03
CABG 189 40 113 15 .0001
Thoracic aorta repair 5 1.0 0 0 .009
Stented bovine pericardial prosthesis. †Cryopreserved aortic allograft.
ABG, Coronary artery bypass grafting; NYHA, New York Heart Asso-
iation.5 years. In total, 3892 patient-years of data were available for
and Cardiovascular Surgery ● Volume 131, Number 3 559
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CDnalysis. We considered time-related estimates to be reliable to
2 years.
End points. The primary end point was valve explantation for
VD determined from echocardiographic, surgical, and pathologic
ndings. SVD is defined as any change in function of a prosthesis
esulting from intrinsic abnormality causing stenosis or regurgita-
ion.12 However, SVD is a continuous process that is never con-
inuously monitored (opportunistic echocardiographic estimates
f prosthesis status have been reported for the premarket multi-
nstitutional cohort13). Therefore, we chose explantation for SVD
s a hard end point.
We recognize that the decision for, and timing of, explant
epends on many factors. We cannot estimate how many patients
ad even severe, possibly symptomatic SVD who were not re-
erred for reoperation. Autopsies were performed in an insufficient
umber of patients to ascertain prosthesis status. The secondary
nd point was death within 30 days of explantation.
ata Analysis
onparametric estimates of time-related events were obtained
sing the Kaplan-Meier method.14 A parametric method was used
o resolve the number of phases of instantaneous risk (hazard
unction) and to estimate its shaping parameters.15 (For addition-
l details, see http://www.clevelandclinic.org/heartcenter/hazard.)
azard functions were obtained both for the combined group of
222 patients and for each prosthesis-related group.
A large number of patient variables (and donor variables for
atients receiving allografts) were examined, and age at implan-
ation was the only factor found to be associated with SVD
Appendix E1). Therefore, subsequent analysis focused on the
nfluence of age. This included forcing prosthesis type, age, and
ge–type interactions into parametric models. Bootstrap bagging
1000 replications) was used to suggest the transformation of scale of
ge required to linearize it with respect to model assumptions.16,17
Because of age bias in prosthesis choice, the primary multiva-
iable analysis was supplemented by 3 verification analyses. First,
e stratified patients by age groups and compared explantation for
VD within groups. Although the number of patients receiving
ach prosthesis type was widely discrepant within these age
roups, the number of explants on which comparisons primarily
epend was similar for each age group for pericardial prostheses.
econd, we performed multivariable subgroup analysis parallel to
he analysis for patients under age 60. Third, we compared the
revalence of SVD in propensity-matched pairs. For this, we used
ogistic regression analysis to develop a nonparsimonious model of
he propensity to insert allograft valves.18,19 From this, a propen-
ity score was calculated for each patient, and this score was used
o pairwise match patients.
Depictions of the age effect were made using the specific
azard function and specific age effect for each valve type (no-
ograms).20 Confidence limits (CLs) of parametric estimates are
symmetric but equivalent to 1 SE (68%).
esults
alve Explantation
inety-five pericardial valves were explanted, 70 (74%)
or SVD (Table 2). Forty-six allografts were explanted, 27
59%) for SVD. w
60 The Journal of Thoracic and Cardiovascular Surgery ● Marcxplantation for SVD
t 5, 10, 12, 15, and 19 years, risk-unadjusted freedom from
xplantation for SVD of pericardial prostheses was 99.5%,
3%, 87%, 73%, and 47%, respectively, and at 5, 10, and 12
ears, these figures were 98.0%, 91%, and 77% for allo-
rafts (Figure E1, A). Instantaneous risk of both pericardial
rosthesis and allograft explantation for SVD (hazard func-
ion) accelerated exponentially; however, in addition, for
llografts there was also a constant hazard due to a small
umber of early allograft explantations (Figure E1, B) This
onstant hazard was largely accounted for by cusp fibrosis
n 3 patients, cusp calcification in 3, and noncalcific degen-
ration in 2, all occurring within 3 years of implantation.
ge and Explantation for SVD
he apparently higher risk of explantation for SVD among
atients receiving allografts compared with pericardial pros-
heses was related to their younger average age at implan-
ation (Table 3). Within age groups, freedom from explan-
ation for SVD was nearly superimposable (Figures 1, E2,
nd E3). Although the number of events was small, the risk
f SVD was confirmed as being nearly identical in propensity-
atched pairs of patients receiving allograft versus pericardial
rostheses (P  .2; Figure 2).
Within the subgroup of patients under age 60, there was
nsufficient power to detect an age-related difference in
xplantation for SVD among patients receiving allografts,
ue to both short follow-up and elimination of older patients
ho experienced few events (see Table 3). However, it was
qually true that their age-related deterioration was similar
o that of pericardial prostheses for which more information
ABLE 2. Pathophysiology and indication for explantation
athophysiology and indication
Pericardial* Allograft †
No. % No. %
athophysiology
Stenosis 18 27 2 5.3
Regurgitation 30 45 30 79
Mixed 19 28 6 16
Uncertain 28 8
ndication
SVD 70 74 27 59
Endocarditis 10 11 17 37
Incidental‡ 11 12 0 0
Technical 0 0 2 4.3
Periprosthetic leakage 1 1.1 0 0
Uncertain 3 3.2 0 0
otal 95 100 46 100
VD, Structural valve deterioration. *Stented bovine pericardial prosthesis.
Cryopreserved aortic allograft. ‡Generally during subsequent coronary
rtery bypass grafting or mitral valve replacement.as known (see Table 3).
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A
CDThus, overall multivariable analysis, stratified actuarial
nalysis, subgroup analysis, and propensity matching all sup-
orted the observation that through at least 12 years, age-
pecific risk of explantation for SVD was similar for both
llografts and pericardial bioprostheses.
hirty-Day Mortality After Explantation
wo patients in the allograft group (4.3%; CL, 1.4%-10%)
nd 4 in the pericardial group (4.2%; CL 2.1%-7.5%) died
ithin 30 days of explantation for any reason. No patient in
he allograft group (0%; CL, 0%-7.2%) and 3 of 4 patients
n the pericardial group (4.2%; CL, 1.9%-8.4%) died within
0 days of explantation for SVD.
From available data, failing allografts were replaced with
nother allograft in 16%, a mechanical prosthesis in 52%,
nd a biologic prosthesis in 32%. In contrast, only 2% of
xplanted pericardial valves were replaced with an allograft
t reoperation; mechanical and biologic prostheses were
sed in 45% and 53%, respectively.
iscussion
his study focused on biologic valve durability in noneld-
rly patients for 2 reasons. First, such patients are increas-
ngly seeking valve alternatives that avoid anticoagulation.
econd, we had begun to question our assumptions about
llograft durability in such patients. In this comparison,
ryopreserved allografts and stented bovine pericardial valves
equired explantation for SVD at similar age-specific rates.
llograft and Pericardial Valve Deterioration
xplantation for allograft SVD in this series (23% at 12
ears) was similar to results published by O’Brien and
olleagues.21 In their experience, 39% of patients between
ABLE 3. Age and risk of structural valve deterioration
isk factor Coefficien
ericardial prostheses
Late hazard phase
Younger age* 0.59
llografts
Late hazard phase
Younger age* 0.82
omparison
Early hazard phase
Younger age and allografts† 1.50
Late hazard phase
Pericardial prosthesis 0.49
Younger age* 0.70
Younger age and pericardial prosthesis* 0.099
(Age/50)4 power transformation. †(50/Age) inverse transformation. ‡Whe
emoved, the significance of age association becomes P  .0001 in overages 41 and 60 underwent reoperation by 15 years postop- o
The Journal of Thoracicratively, but this rapidly increased to 63% at 18 years.
und and colleagues22 at the Royal Brompton and Harefield
ospitals have described 3 hazard phases for allograft
issue failure: a low early phase, an accelerating phase
etween 10 and 20 years after operation, and a period of
ow and constant risk thereafter. This increasing rate of
eoperation between 10 and 20 years postreplacement is the
ost likely explanation for the variability of published rates
f reoperation at 15 years. Our data cannot address risk
eyond 20 years.
The Carpentier-Edwards pericardial prosthesis is a second-
eneration stented bovine valve that is low-pressure fixed in
lutaraldehyde and treated with the anticalcification agent
olysorbate (Tween) 80. The majority of these valves have
een used in older patients, in whom they have been quite
urable. For patients age 65 or older, the chance of reop-
ration is less than 10%.8 The excellent hemodynamic pro-
le and ease of inserting the prostheses led to liberalizing
heir use in younger patients during the premarket phase of
heir introduction.
oung Age and SVD
ounger age at implantation is associated with accelerated
VD among all stented xenograft aortic valves, including
ericardial valves.8 For allografts, published data are less
efinitive. In O’Brien and colleagues’ series,9 only patients
elow age 20 had greater rates of reoperation than older age
ohorts. In fact, patients between ages 21 and 40 had an
stimated 20-year freedom from reoperation of 77%, al-
hough for patients between ages 41 and 60, that figure was
7%. These somewhat erratic results for isolated age groups
mphasize the importance of analyzing the entire spectrum
all analysis Patients aged <60 y
D P value Coefficient SD P value
.0001 0.48 0.23 .04
.07 0.55 0.54 .3
.01 1.24 0.72 .09
.3 0.41 0.54 .4
.1‡ 0.46 0.48 .3
.8 0.029 0.52 .9
significant factors (type of prosthesis and its interactions with age) are
lysis and P  .04 in the subgroup of patients under age 60.Over
t  S
0.10
0.46
0.61
0.48
0.42
0.43
n nonf the relation of age to explantation for SVD, in keeping
and Cardiovascular Surgery ● Volume 131, Number 3 561
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A
CDith the philosophy of “continuity in nature.”23,24 In Lund
nd associates’22 series, both allograft donor age and patient
ge were related to SVD. A meta-analysis–microsimulation
odel predicted only 20% freedom from allograft SVD at
5 years and demonstrated an age-dependent effect such
hat patients below age 55 had between a 60% and 80%
ifetime risk of reoperation for allograft failure.25 When the
ull spectrum of age was considered so that contrasts could
ecome manifest, we, too, found younger age at implanta-
ion increased the rate of explantation for SVD for both
Figure 1. Freedom from explantation for structural
bioprostheses (open circles) and allografts (closed cir
asymmetric 68% confidence limits equivalent to 1 SE. A
There were 406 patients with allografts experiencing 19
with pericardial bioprostheses experiencing 23 events
to 60 years of age at valve replacement. Three patient
could not be determined were excluded. There were 2
20 at risk at 5 and 10 years) and 84 patients with peric
risk at 5 and 10 years; P  .7). C, Patients 60 years and
allografts experiencing 1 event (70 and 8 at risk at 5 an
experiencing 23 events (254 and 131 at risk at 5 and 1alves. g
62 The Journal of Thoracic and Cardiovascular Surgery ● MarcOur age-based comparison cannot exclude subtle differ-
nces in the 2 cohorts that may have affected the threshold
or reoperation, but it is reasonable to believe that most
oung adults in whom important SVD was detected would
e offered reoperation.
echnical Challenges
eoperations for allograft failure can be challenging. Allo-
raft wall and valve calcification may be encountered in
0% of allograft reoperations.26 Nevertheless, both allo-
deterioration (SVD) of stented bovine pericardial
) used for aortic valve replacement. Vertical bars are
ents 50 years of age and younger at valve replacement.
ts (186 and 32 at risk at 5 and 10 years) and 51 patients
nd 29 at risk at 5 and 10 years; P  .5). B, Patients >50
ose indication for pericardial prosthesis explantation
atients with allografts experiencing 7 events (103 and
l bioprostheses experiencing 24 events (67 and 46 at
r at valve replacement. There were 135 patients with
years) and 340 patients with pericardial bioprostheses
rs; P  .9).valve
cles
, Pati
even
(43 a
s wh
03 p
ardia
olde
d 10
0 yearaft and pericardial valve re-replacement can be accom-
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A
CDlished with low mortality. This is crucial if allografts
nd pericardial valves are to be implanted in nonelderly
atients.
imitations
VD is not an event but a time-related process, sporadically
onitored, with many factors considered before a biopros-
hesis is explanted. We do not know how many patients
uffered severe symptoms secondary to a dysfunctional
alve and either died or were not considered for explanta-
ion. A detailed echocardiographic follow-up of allografts
ound only 5.4% of root replacements had more than 2
egurgitation and only 1.9% had moderate to severe aortic
tenosis at a mean follow-up of 4.2 years.27 Similarly, in
chocardiographic follow-up of aortic pericardial prosthe-
es, mean gradients increased only slightly, and regurgita-
ion increased slowly over 10 years.13 This suggests that the
nderestimation of valve dysfunction is small.
One way to investigate the degree of underestimation is
o assume that any deterioration in clinical status is second-
ry to SVD. Indeed, the Society of Thoracic Surgeons/
merican Association for Thoracic Surgery definition of
VD includes “any change in function (a decrease of one
ew York Heart Association functional class or
ore) . . . of an operated valve resulting from intrinsic ab-
ormality of the valve that causes stenosis or regurgita-
ion.”12 However, many other factors can cause functional
lass deterioration unrelated to prosthesis deterioration. Pre-
iously, we have found no relation between young age, a
trong correlate of SVD, and time-related deterioration of
igure 2. Freedom from explantation for structural valve deteri-
ration of stented bovine pericardial bioprostheses (open circles)
nd allografts (closed circles) used for aortic valve replacement
n propensity-matched patients. Vertical bars are asymmetric
8% confidence limits equivalent to 1 SE.ew York Heart Association functional status in the peri- J
The Journal of Thoracicardial prosthesis cohort (P  .8).13 Therefore, we have not
sed change in New York Heart Association class as a
urrogate marker for SVD.
This study has several other limitations. First, for peri-
ardial prostheses, it represents a nonrandomized, multi-
nstitutional study. However, these patients provide the
ongest follow-up and age spectrum for this prosthesis and
hus the most certainty for time-related estimates of explan-
ation for SVD. Second, at our institution, allografts were
sed preferentially in young adults and those with endocar-
itis. In addition, their follow-up is shorter than for pericardial
alves, and thus time- and age-related risk of explantation for
VD is not as securely estimated. In contrast, although fewer
ericardial prostheses were implanted in young adults, their
onger follow-up provided equivalent or better information
bout deterioration at younger ages than did that for allo-
rafts. Third, although there were clear differences between
he groups of patients receiving pericardial and allograft
rostheses, there was little evidence that factors other than
ge were associated with SVD. Thus, both age stratification
nd propensity matching on numerous clinical factors dem-
nstrated age-specific equivalency of explantation for SVD
or these 2 groups. Fourth, clinical criteria or thresholds for
xplantation of a dysfunctional valve were not standardized
r defined.
linical Inferences
his study was not motivated by a desire to determine which
ortic valve prosthesis is best for patients younger than current
uidelines for implanting bioprostheses. Rather, we were
otivated by our observation that an increasing number of
atients are interested in a valve that does not require
nticoagulation and by our questioning whether allograft
urability might be less than generally assumed or pericar-
ial prosthesis durability better than assumed. For context, we
ompared our findings for allografts with those of the pros-
hesis we most commonly implant, the stented Carpentier-
dwards PERIMOUNT valve. Alternatives include the Ross
rocedure, stentless xenografts, valve repair, and mechani-
al prostheses. Our results provide estimates of age-related
ccurrence of SVD following allograft and pericardial aor-
ic valve replacement and the risk of re-replacement, which
re equivalent. These results provide information for weigh-
ng the risks and benefits of choosing a pericardial prosthe-
is in patients younger than current age guidelines who wish
o avoid anticoagulation.
We thank Colleen Laffey, RN, Tanya Ashinhurst, BS, and
ocelyn Piskach, RN, BSN, for assisting with cross-sectional
ollow-up; Linda DiPaola, BS, for assembling the data for analy-
is; and Tess Parry, BS, for editorial assistance. Analysis of
atient and donor factors for allograft SVD was performed by
ennifer White, MS.
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Appendix E1. Variables Analyzed
For Allografts
Demography. Gender, age, weight, height, body surface area,
body mass index, ethnicity, blood type.
Clinical. New York Heart Association functional class, emer-
gency operation.
Aortic valve disease etiology and pathophysiology. Etiology
(rheumatic, degenerative, infectious), pathophysiology (regurgita-
tion, aortic stenosis, mixed lesion), bicuspid valve, anulus di-
ameter.
Cardiac comorbidity. Previous myocardial infarction, number
of diseased (50% or greater diameter stenosis) coronary systems,
previous cardiac operation.
Noncardiac comorbidity. Smoking history, pharmacologically
treated diabetes, hypertension, peripheral vascular disease, chronic
obstructive pulmonary disease, creatinine, blood urea nitrogen.
Concomitant procedures. Coronary artery bypass grafting, mi-
tral valve repair, mitral valve replacement, tricuspid valve repair.
Experience. Date of operation.
Donor variables. Gender, age, anulus diameter, blood type.
Donor–recipient mismatch. Gender difference, age differ-
ence, blood type differences, difference in anulus diameter.
For Pericardial Valves
Demography. Gender, age, weight, height, body surface area,
body mass index.
Clinical. New York Heart Association functional class, emer-
gency surgery.
Aortic valve disease etiology and pathophysiology. Etiology
(rheumatic, degenerative, infectious), pathophysiology (regurgita-
tion, aortic stenosis, mixed lesion).
Cardiac comorbidity. Previous aortic valve replacement, aor-
tic aneurysm repair.
Concomitant procedures. Coronary artery bypass grafting,
mitral valve repair, mitral valve replacement, tricuspid valve re-
pair, ascending aorta repair.
Experience. Date of operation.
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TABLE E1. Patient characteristics and operative details in patients under age 60
Variable
Pericardial* (n  138) Allograft † (n  609)
P valueNo. % No. %
Age (y) .0001
30 5 3.6 47 7.7
30-40 19 14 154 25
40-50 27 20 205 34
50-60 87 63 203 33
Gender .3
Men 97 70 455 75
Women 41 30 154 25
NYHA class .02
I 17 12 117 19
II 71 52 338 56
III 40 29 122 20
IV 9 6.6 32 5.3
Unavailable 1 0
Previous cardiac operation 18 13 162 27 .0008
Endocarditis 19 14 128 21 .05
Concomitant procedure
Repair or replacement of another valve
Mitral repair 10 7.2 75 12 .09
Mitral replacement 10 7.2 4 0.7 .0001
Tricuspid repair 1 0.7 13 2.1 .3
CABG 32 23 70 11 .0003
Thoracic aorta repair 2 1.4 0 0 .03
CABG, Coronary artery bypass grafting; NYHA, New York Heart Association. *Stented bovine pericardial prosthesis. †Cryopreserved aortic allograft.
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Figure E1. Explantation for structural valve deterioration (SVD) of
stented bovine pericardial bioprostheses and allografts used for
aortic valve replacement. A, Freedom from explantation for SVD.
Symbols represent each event, positioned according to the Kaplan-
Meier method; open circles represent the pericardial group, and
open squares, the allograft group. Vertical bars are asymmetric
confidence limits equivalent to 1 SE. Numbers in parentheses are the
number of traced patients. Solid lines are parametric estimates
enclosed within dashed confidence limits equivalent to 1 SE.
B, Instantaneous risk of explantation for SVD (hazard function). The
model formed for allografts consisted of a constant hazard phase
(0.35% per year) and a late rising hazard phase of Weibull shape
(hazard  1.6  106 t 4.6, where t  time in years since implanta-
tion); that for pericardial prostheses consisted of a Weibul late
phase (hazard  1.4  105 t 3.7).
Figure E2. Freedom from explantation for structural valve deteri-
oration (SVD) according to age at implantation. Equations from
separate hazard functions for each type of prosthesis (Table 3)
were solved for 4 specific ages at index operation. Solid lines are
parametric estimates enclosed within dashed confidence limits
equivalent to 1 SE. A, Age 40 years. B, Age 50 years. C, Age 60
years.
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Figure E3. Probability of explantation for structural valve deteri-
oration (SVD) by 12 years as a function of age at implantation.
Equations from separate hazard functions for each type of
valve (Table 3) were solved at 12 years as a continuous
function of age at index operation. Solid lines are point esti-
mates. Wide dashed lines are confidence limits for allograft
estimates, and fine dashed lines are those for pericardial
prostheses.
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